申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2019243535A1
公开(公告)日:2019-12-26
The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors of formula (I). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.
本发明涉及式(I)的O-GIcNAc水解酶(OGA)抑制剂。该发明还涉及包含这种化合物的药物组合物,用于制备这种化合物和组合物的方法,以及利用这种化合物和组合物预防和治疗OGA抑制对其有益的疾病的应用,特别是τ蛋白病,如阿尔茨海默病或进行性核上性麻痹症;以及伴有τ病理的神经退行性疾病,特别是由C90RF72突变引起的肌萎缩侧索硬化和颞叶前叶痴呆症。